Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2CNS 2Plasma cell 1Head & Neck 1

Conditions

Prostatic Neoplasms 2

Interventions

Magnetic Resonance Spectroscopy 63Specimen Handling 58pembrolizumab 40enzalutamide 38Nivolumab 32Gemcitabine 30Docetaxel 28Biopsy 25Prednisone 23Abiraterone Acetate 21apalutamide 20Androgen Antagonists 19Radiosurgery 18Cisplatin 18darolutamide 16cabozantinib 16abiraterone 16Radiotherapy 16enfortumab vedotin 15Radiation 14Ipilimumab 13belzutifan 12Pluvicto 12Mitomycin 12olaparib 11erdafitinib 11durvalumab 11atezolizumab 11X-Rays 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
fluciclovine F-18 × Genitourinary × 30 days × Clear all
NCT07569926 2026-06-02

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

Blue Earth Diagnostics

Phase 4 Not yet recruiting
142 enrolled
Genitourinary

Prostatic Neoplasms

NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡